Paul Tudor Jones Rubius Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $16,210 - $122,709	-20,520 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $87,210 - $213,408	20,520 New	20,520 $113,000
Q4 2021 Feb 14, 2022	SELL	$9.68 - $17.74 $446,015 - $817,388	-46,076 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $810,937 - $1.19 Million	46,076 New	46,076 $824,000
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $82,950 - $331,079	-10,343 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $158,324 - $326,755	-37,429 Reduced 78.35%	10,343 $79,000
Q3 2020 Nov 16, 2020	BUY	$4.65 - $6.25 $142,285 - $191,243	30,599 Added 178.18%	47,772 $239,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $6.88 $68,863 - $118,150	17,173 New	17,173 $103,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.